AB Science (ABSCF) announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using its lead compound masitinib, based on preclinical data. This new US paten ensures intellectual property protection for masitinib until November 2040.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks